Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2017 May 12;141(2):775–777.e6. doi: 10.1016/j.jaci.2017.04.032

Figure 1.

Figure 1

AIT-treated patients exhibit reduced Tfh frequencies compared to untreated allergic and non-allergic controls. a: Representative Tfh cell staining in an allergic, AIT-treated and non-allergic patient. Dashed boxes indicate the total Tfh population (black), CXCR5lo (blue) and CXCR5hi (red) populations. b: Tfh cell percentage in an allergic (n=25), AIT-treated (n=32) and non-allergic (n=13) patients. c: Quantification of CXCR5 gene expression in CXCR5hi and CXCR5lo sorted cells. d: MA plots comparing fold changes of gene expression between CXCR5hi and CXCR5lo cells vs. average gene expression. Genes with significant adjusted p-values are colored in red e: Heatmap of differentially expressed genes in CXCR5hi vs CXCR5lo samples from allergic and AIT-treated individuals.